----item----
version: 1
id: {F76C7CE2-F66E-486F-A3CE-8926C9E2C6F0}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/12/01/CTI BioPharma appoints Alan Burnett lead myeloid diseases
parent: {704BB214-984D-4FA9-81BA-16097208AE7E}
name: CTI BioPharma appoints Alan Burnett lead myeloid diseases
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: c830c00e-7378-4bc6-a64e-7bfead6e6578

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 77

{1D288E18-BAFF-4498-B284-EF9BC8D32E30}|{8B2376D2-D914-41D6-9402-D3CD38CABF23}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 58

CTI BioPharma appoints Alan Burnett lead, myeloid diseases
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 57

CTI BioPharma appoints Alan Burnett lead myeloid diseases
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 615

<p>CTI BioPharma has named Dr Alan K Burnett therapeutic area lead for myeloid disease. Dr Burnett was most recently professor and head of the department of hematology in the Institute of Cancer and Genetics at Cardiff University. He will be responsible for creating and implementing the strategic development program for CTI's compounds in myeloid malignancies with a major focus on supplementing the company's current late-stage development programs in chronic myeloproliferative diseases and international development programs in other myeloid malignancies such as acute myeloid leukemias and myelodysplasia.</p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 615

<p>CTI BioPharma has named Dr Alan K Burnett therapeutic area lead for myeloid disease. Dr Burnett was most recently professor and head of the department of hematology in the Institute of Cancer and Genetics at Cardiff University. He will be responsible for creating and implementing the strategic development program for CTI's compounds in myeloid malignancies with a major focus on supplementing the company's current late-stage development programs in chronic myeloproliferative diseases and international development programs in other myeloid malignancies such as acute myeloid leukemias and myelodysplasia.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 57

CTI BioPharma appoints Alan Burnett lead myeloid diseases
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20151201T080626
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20151201T080626
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20151201T080626
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC027531
----field----
field: {2C985172-2B37-4CFE-AEDE-2A42EC833941}
name: Content Type
key: content type
content-length: 38

{832554E5-EC9E-4747-8623-6770D36CAF32}
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 58

CTI BioPharma appoints Alan Burnett lead, myeloid diseases
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{090E9A04-9B4B-4986-8BAF-06A6B07B978D}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 13

Headline News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

356071
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042233Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

c830c00e-7378-4bc6-a64e-7bfead6e6578
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042233Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
